메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한산부인과학회 Obstetrics & Gynecology Science Obstetrics & Gynecology Science 제48권 제10호
발행연도
2005.1
수록면
2,261 - 2,284 (24page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
The current therapy for patients with advanced ovarian cancer consists of maximal cytoreductive surgery followed by six cycles of combination chemotherapy with paclitaxel/carboplatin. With this therapy, approximately 75% of patients with advanced epithelial ovarian cancer will achieve a clinical complete remission (normal CT, normal CA-125, normal pelvic exam), but the majority of patients will recur. Therefore, the strategy to consolidate and to prolong the duration of response is very important because cure for patients with recurrent disease is highly improbable. Several treatments for consolidation/maintenance have been attempted, such as whole abdominal radiation, intraperitoneal chromic phosphate, radioimmunotherapy, intraperitoneal chemotherapy, high-dose chemotherapy with hematopoietic support, prolonged administration of the first-line regimen, second-line single-agent chemotherapy, and biological agents. Unfortunately, many clinical studies have been conflicting, inconclusive, and generally disappointing. Recently, the GOG, together with SWOG, showed that prolonged treatment with single-agent paclitaxel (175 mg/m2 every 4 weeks) significantly improved the progression- free survival of complete responders to paclitaxel/platinum-based chemotherapy. Alternative less toxic, and more effective schedules of administration of chemotherapy (i.e. weekly paclitaxel) might provide a better balance between quality of life and anti-tumor activity in patients previously exposed to chemotherapy.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0